Vaccines targeting mutant KRAS to prevent pancreatic cancer
Mutant KRAS targeted vaccines for the interception of pancreatic cancer development
This study is testing a new vaccine that helps the immune system fight pancreatic cancer by targeting specific gene changes, and it's for people at high risk of developing this cancer or those who have already had it removed.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10940953 on NIH RePORTER |
What this research studies
This research focuses on developing vaccines that target specific mutations in the KRAS gene, which are commonly associated with pancreatic cancer. By identifying individuals at high risk for pancreatic ductal adenocarcinoma (PDAC) and utilizing genetic testing and imaging techniques, the study aims to intercept the progression of cancer from premalignant lesions. The vaccine is designed to stimulate the immune system, particularly CD4 T cells, to recognize and attack cells with these mutations, potentially halting the development of cancer. Patients who have had resected PDAC may also benefit from this approach, as it aims to improve disease-free survival.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of pancreatic cancer or those who have specific genetic mutations associated with increased cancer risk.
Not a fit: Patients with advanced pancreatic cancer who are already symptomatic or have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of pancreatic cancer by preventing its progression in high-risk individuals.
How similar studies have performed: Previous research has shown promising results with similar vaccine approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Zaidi, Neeha — Johns Hopkins University
- Study coordinator: Zaidi, Neeha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.